The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
about
ALK Signaling and Target Therapy in Anaplastic Large Cell LymphomaUse of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilizationBcl-2 antagonists: a proof of concept for CLL therapyAurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activityABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.Phase 2 study of weekly bortezomib in mantle cell and follicular lymphomaBcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Using functional genomics to overcome therapeutic resistance in hematological malignancies.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraCombined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent mannerCarfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoThe histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideProteasome inhibitors in mantle cell lymphomaMolecular pathogenesis of mantle cell lymphoma.ABT-737 synergizes with Bortezomib to kill melanoma cells.Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivoVinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.Targeting the BCL-2 family in malignancies of germinal centre origin.Novel disease targets and management approaches for diffuse large B-cell lymphoma.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.
P2860
Q21129306-535EE91C-F384-43B8-8BD9-D104DC1E6A36Q21562635-E32A63BF-EF4B-4566-996F-6CB478F47ECAQ26823996-1F14BB4D-BDF5-4DE4-A79E-D31254C026BDQ27346432-5E822E96-69CA-4CB0-8FC2-3F7F02D43B4EQ28487756-6D6A3200-48B9-4027-838B-297599D15A1EQ33405436-9D9BC391-14CC-491D-9444-56C12320962BQ33414307-3462C3ED-EEAC-4E92-B06E-DEA0F3925F06Q33669018-C0C55E89-A1BE-47AC-B84E-87ED9A9F10BDQ33989217-137CAC7C-3475-408C-BC4A-1DBE4A42B5ADQ34173253-C11F278E-5F94-4FDF-A3A6-768410C0AB91Q34401328-8C51E2A6-2A7A-48E3-9A6A-91A815459E5EQ34568868-49868C33-129A-4B82-B20D-BF37A275BE75Q34683589-40372ADA-5879-487E-A2C2-E0B425550975Q34685414-A8A158DE-3CC6-42BB-BA7B-D233F1029F05Q35206717-4900B870-6EE8-447B-B512-5A1587F33033Q35223868-CD8DF554-CF89-4F97-BCEE-C793B9C07B93Q35779325-6F514465-3416-4FF4-ADEB-1B64782B6B86Q35989980-D5E9D5FD-391C-482B-BBBB-604ACDAA57C6Q36028745-E50DF1F8-5692-44B1-BD4C-D16B972C9EB4Q36290246-B816664A-FD77-472B-AB83-03FD38B1CD29Q36425600-F1E66BE2-C181-43EE-B0FA-3B4F8A228548Q36619787-59084DAB-518F-4A34-9911-BF45F8A808B5Q36697045-BEC71487-3BE7-4E75-87FA-9E64E94CABF6Q37092954-201F881B-5C26-43CF-BE9D-7D4A74F4DC9BQ37564773-8D9AE5F6-B548-46AA-A843-6766B89ED52DQ37634558-068C2566-2A58-4690-9A2F-CD14B912AAD1Q37775632-3C6CCC28-C6B1-4290-8CD8-D5F324EA30E6Q37865381-751EB806-6D20-40D3-90C2-261FFC8CD417Q37874926-65890CB0-D67D-4575-8ADB-6A8F06EF0FCDQ37983083-32642B7C-9C20-47CD-8BB4-8F7F5D813558Q38061861-8A14C344-8C8D-469F-A178-E294946E3345Q38543771-BA77A8F4-7D1C-4B6B-9AC6-E710AC10DB95Q38975047-87AC6F16-AFBB-4FF8-AD98-A59863204F78Q39177637-D59142CC-02EA-4B36-9FC2-54A8674F7A98Q39413018-2C00E323-2A36-4B9F-B1C7-DF3B5ECEE276Q39414811-0F0DE82E-9D06-4144-9DB9-3BA25889CDA9Q39443671-103BA841-B0FD-4703-BC56-EC39C27A3D4DQ39608912-C7A5B413-FC46-42B6-AB45-3689B3C2635DQ39626230-C21683F2-EEE7-4638-8E1F-D5148EB51D9FQ39832788-709109DE-ADB4-4003-A2BD-C4C6A7F28682
P2860
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@ast
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@en
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@nl
type
label
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@ast
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@en
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@nl
prefLabel
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@ast
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@en
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@nl
P2093
P1433
P1476
The BH3-only mimetic ABT-737 s ...... tors in lymphoid malignancies.
@en
P2093
Jeffrey R Gardner
Katia Manova
Luigi Scotto
Mark L Heaney
Mithat Gonen
Owen A O'Connor
Richard R Furman
Volodia D Gueorguiev
P304
P356
10.1182/BLOOD-2007-12-130781
P407
P577
2008-06-30T00:00:00Z